Theralase Technologies Inc. (CVE:TLT – Get Free Report) shares traded down 2.7% during trading on Monday . The stock traded as low as C$0.18 and last traded at C$0.18. Approximately 392,474 shares traded hands during trading, an increase of 57% from the average session volume of 250,480 shares. The stock had previously closed at C$0.18.
Theralase Technologies Stock Down 2.7%
The business has a 50-day simple moving average of C$0.25 and a two-hundred day simple moving average of C$0.27. The company has a debt-to-equity ratio of 22.13, a quick ratio of 3.40 and a current ratio of 1.37. The company has a market capitalization of C$53.22 million, a price-to-earnings ratio of -12.86 and a beta of -0.57.
Theralase Technologies Company Profile
Theralase Technologies Inc, a clinical stage pharmaceutical company, engages in the research and development of light activated photo dynamic compounds (PDCs) and their associated drug formulations to treat cancers, bacteria, and viruses in Canada, the United States, and internationally. It also designs, develops, manufactures, and markets patented and proprietary super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions.
Further Reading
- Five stocks we like better than Theralase Technologies
- The AI Boom Is Turning This Cable Maker Into a Stock to Watch
- A Star Investor Just Trimmed Amazon—Here’s What It means
- Wendy’s Deal Buzz May Give Fast-Food Investors a New Reason to Look
- Home Depot Analysts See a Path to $375 and Beyond
Receive News & Ratings for Theralase Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theralase Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
